Seglitide
Alternative Names: L 363586; MK 678Latest Information Update: 12 Feb 2008
At a glance
- Originator Merck & Co
- Developer Merck & Co; Nonindustrial source
- Class Antihyperglycaemics; Cyclic peptides; Nootropics
- Mechanism of Action Somatotropin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Cancer; Diabetes mellitus; Diabetic retinopathy; Macular degeneration
Most Recent Events
- 20 Jul 2006 Discontinued - Preclinical for Macular degeneration in USA (unspecified route)
- 20 Jul 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 07 May 2003 Discontinued - Preclinical for Diabetic retinopathy in USA (unspecified route)